PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsGozetotide alf-18
Gozetotide alf-18
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
156 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Prostatic neoplasmsD011471—C61303219648126
RecurrenceD012008——4—61415
NeoplasmsD009369—C8035—1614
AdenocarcinomaD000230——3511212
Castration-resistant prostatic neoplasmsD064129——33—319
Urogenital neoplasmsD014565EFO_0003863D0712—114
Prostatic diseasesD011469—N42.912—1—3
Neoplasms by siteD009371———1—1—2
Male genital diseasesD005832EFO_0009555N50.9—1—1—2
Male genital neoplasmsD005834———1—1—2
Show 5 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ProstatectomyD011468————1——1
RadiotherapyD011878————1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CarcinomaD002277—C80.064——312
Renal cell carcinomaD002292EFO_0000376—42——27
Breast neoplasmsD001943EFO_0003869C5022——26
Thyroid neoplasmsD013964EFO_0003841——1——23
Triple negative breast neoplasmsD064726———2———2
Hepatocellular carcinomaD006528—C22.0—2———2
Liver neoplasmsD008113EFO_1001513C22.0—2———2
Thyroid diseasesD013959—E00-E07—1——12
Female genital neoplasmsD005833———1———1
Intraductal carcinoma noninfiltratingD002285—D05.1—1———1
Show 1 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Positron emission tomography computed tomographyD000072078——3———14
Neoplasm metastasisD009362EFO_0009708—3———14
Neuroendocrine carcinomaD018278——1———23
Brain neoplasmsD001932EFO_0003833C711———23
GliomaD005910EFO_0000520—2———13
Head and neck neoplasmsD006258——1———12
Kidney neoplasmsD007680EFO_0003865C641———12
Lobular carcinomaD018275EFO_0000570—1————1
Invasive hydatidiform moleD002820—D39.21————1
Ovarian neoplasmsD010051EFO_0003893C561————1
Show 7 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Neuroendocrine tumorsD018358EFO_1001901D3A.8————55
GlioblastomaD005909EFO_0000515—————33
Positron-emission tomographyD049268——————33
Gastrointestinal neoplasmsD005770—C26.9————22
Digestive system neoplasmsD004067——————11
Papillary thyroid cancerD000077273——————11
Medullary carcinomaD018276——————11
Multiple myelomaD009101—C90.0————11
Plasma cell neoplasmsD054219——————11
Urologic neoplasmsD014571—C64-C68————11
Show 13 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
No data
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 66 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
42 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use